Incubate’s John Stanford on why MFN is voluntary in name only — and why the moonshot is the first casualty of drug pricing pressure.
Feature|Articles|June 2, 2026
The Pharma Patent Cliff Explained: What It Is and How Companies Navigate It
Author(s)Mike Hollan
Between 2026 and 2030, billions of dollars in revenue will be at risk due to expiring patents and periods of exclusivity.
Advertisement
Advertisement
In the coming years, about 200 drugs will have their patents or terms of exclusivity come to an end. These drugs make up an estimated $400 billion in revenue for the pharma industry. While this isn’t the first patent cliff to hit the industry, it is the largest its ever faced.
Related to this article
Sun Pharma's IL-23 inhibitor tildrakizumab gains a psoriatic arthritis indication; the announcement cited no phase 3 efficacy figures.
Brox.AI's co-founder and CEO on why telling an AI to pretend to be a doctor isn’t the same as cloning one — and why that distinction matters for pharma.
Brock.AI’s Hamish Brocklebank on recruiting 8% of all US pancreatic cancer prescribers — paying $2,000 an hour, offering equity, and triple opt-in consent.
Brox.AI’s Hamish Brocklebank on three levels of digital clone use cases — from HCP content testing and GLP-1 price sensitivity modeling to simulating physician adoption after FDA approval.
Shionogi’s Dr. Draica on how XOCOVA blocks viral replication between exposure and symptoms — and why it works even with prior immunity.
Phagenyx’s Chad Hoskins on why AHA/ASA guideline inclusion gives stroke teams a basis to use PES earlier — and what the evidence shows.
Pfizer’s talazoparib-enzalutamide combination moves to earlier line in prostate cancer, with eligibility tied to genetic testing and immature survival data.
Advertisement
Advertisement